Non-motor Effects of Bemdaneprocel for Parkinson’s Disease: 18-month Results from a Phase 1 Study (P9-3.001)Harini Sarva, Viviane Tabar, Claire Henchcliffe et al.|Neurology|2024Cited by 0
Safety, Tolerability, and Clinical Assessment of Bemdaneprocel for Parkinson’s Disease: Results Through 24 Months From a Phase 1 Study (S37.005)Harini Sarva, Viviane Tabar, Suneil K. Kalia et al.|Neurology|2025Cited by 0